New scoring methodology improves the sensitivity of the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Introduction: As currently used, the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) has low sensitivity for measuring Alzheimer’s disease progression in clinical trials. A major reason behind the low sensitivity is its sub-optimal scoring methodology, which can be improved to obtain better sensitivity. Methods: Using item response theory, we developed a new scoring methodology (ADAS-CogIRT) for the ADAS-Cog, which addresses several major limitations of the current scoring methodology. The sensitivity of the ADAS-CogIRT methodology was evaluated using clinical trial simulations as well as a negative clinical trial, which had shown an evidence of a treatment effect. Results: The ADAS-Cog was found to measure impairment in three cognitive domains of memory, language, and praxis. The ADAS-CogIRT methodology required significantly fewer patients and shorter trial durations as compared to the current scoring methodology when both were evaluated in simulated clinical trials. When validated on data from a real clinical trial, the ADAS-CogIRT methodology had higher sensitivity than the current scoring methodology in detecting the treatment effect. Conclusions: The proposed scoring methodology significantly improves the sensitivity of the ADAS-Cog in measuring progression of cognitive impairment in clinical trials focused in the mild-to-moderate Alzheimer’s disease stage. This provides a boost to the efficiency of clinical trials requiring fewer patients and shorter durations for investigating disease-modifying treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Hu, L., & Bentler, P. M. (1999) · Structural Equation Modeling A Multidisciplinary Journal · doi:10.1080/10705519909540118 · Cited by 108,788
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
A Reliability Coefficient for Maximum Likelihood Factor Analysis
Tucker, L. R., & Lewis, C. (1973) · Psychometrika · doi:10.1007/bf02291170 · Cited by 7,330 · cited 5×
“The item characteristic functions also illustrated little sample bias, with good global (RMSEA = 0.039 and TLI = 0.95) and item-level fit (S-X2 was not statistically significant) to response data from the treatment arms of the ADCS clinical trials.”
MethodInfluentialHenson, R. K., & Roberts, J. K. (2006) · Educational and Psychological Measurement · doi:10.1177/0013164405282485 · Cited by 2,454
Marginal Maximum Likelihood Estimation of Item Parameters: Application of an EM Algorithm
Bock, R. D., & Aitkin, M. (1981) · Psychometrika · doi:10.1007/bf02293801 · Cited by 2,339
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
Dynamics of Gray Matter Loss in Alzheimer's Disease
Thompson, P. M., Hayashi, K. M., de Zubicaray, G., Janke, A. L., Rose, S. E., Semple, J., Herman, D., Hong, M. S., Dittmer, S. S., Doddrell, D. M., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-03-00994.2003 · Cited by 1,132
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial
Quinn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., Galvin, J. E., Emond, J., Jack, C. R., Weiner, M., et al. (2010) · JAMA · doi:10.1001/jama.2010.1510 · Cited by 764 · cited 2×
“lysis-of-covariance (ANCOVA) methodology [18–22].”
Cited by
Kueper, J. K., Speechley, M., & Montero-Odasso, M. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170991 · Cited by 424
Lamb, S. E., Sheehan, B., Atherton, N., Nichols, V., Collins, H., Mistry, D., Dosanjh, S., Slowther, A. M., Khan, I., Petrou, S., et al. (2018) · BMJ · doi:10.1136/bmj.k1675 · Cited by 417
Current limitations of neuropsychological tests and assessment procedures
Howieson, D. (2019) · The Clinical Neuropsychologist · doi:10.1080/13854046.2018.1552762 · Cited by 143
“For diseases that produce a predictable cognitive profile, some test batteries have been developed: Alzheimer’s disease (Verma et al., 2015; Weintraub et al., 2009), Huntington disease (Stout et al., 2014), multiple sclerosis (Benedict et al., 2002, 2012), frontal injuries (Dubois, Slachevsky,…”
Lamb, S. E., Mistry, D., Alleyne, S., Atherton, N., Brown, D., Copsey, B., Dosanjh, S., Finnegan, S., Fordham, B., Griffiths, F., et al. (2018) · Health Technology Assessment · doi:10.3310/hta22280 · Cited by 98
“Between the estimation of the sample size and the finalisation of the statistical analysis plan, the literature had moved to suggest that the ADAS-Cog does not measure a single patient trait (cognitive impairment) but rather it measures cognitive impairment in multiple cognitive domains.(86) Therefore, IRT was used to…”
MethodLansdall, C. J., McDougall, F., Butler, L. M., Delmar, P., Pross, N., Qin, S., McLeod, L., Zhou, X., Kerchner, G. A., & Doody, R. S. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2022.102 · Cited by 99
Metadata
- Authors
- Verma, N., Beretvas, S. N., Pascual, B., Masdeu, J. C., Markey, M. K., & Initiative, T. A. D. N.
- Venue
- Alzheimer's Research & Therapy
- Published
- 2015-11-12
- Volume
- 7
- Issue
- 1
- Pages
- 64-64
- ISSN
- 1758-9193 (ISSN-L)
- OpenAlex
- W2102341792
- Cited by
- 59
- References
- 13
- FWCI
- 5.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New scoring methodology improves the sensitivity of the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials. https://app.cochat.ai/papers/10.1186/s13195-015-0151-0
- The paper
- Verma, N., Beretvas, S. N., Pascual, B., Masdeu, J. C., Markey, M. K., & Initiative, T. A. D. N. (2015). New scoring methodology improves the sensitivity of the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-015-0151-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.